Revenue and net profit grew over 15% year-over-year, driven by CNS drug innovation and strong anesthesia product sales. R&D investment rose 13%, with over 70 projects in the pipeline. No interim dividend planned.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.